Literature DB >> 22367298

A study of ΔNp63 expression in lung non-small cell carcinomas.

Daisuke Nonaka1.   

Abstract

Distinguishing between lung adenocarcinoma and squamous cell carcinoma is becoming increasingly important, given the different treatment regimens available. Although histologic subdivision between the two is generally not difficult in differentiated tumors, it can be challenging in poorly differentiated tumors and may require a panel of immunohistochemistry stains. The p63 gene encodes two different N-termini (TA and ΔN). ΔNp63 is selectively expressed in squamous cell carcinoma, whereas TAp63 is not restricted only to it. 4A4, a widely used anti-p63 antibody, identifies both isoforms and is expressed in about 15% of adenocarcinomas, and, although generally focal, its expression can be diffuse. In this study, a total of 150 lung adenocarcinomas and 50 squamous cell carcinomas were immunostained by antibodies for p63 (4A4), ΔNp63 (p40), and TTF-1 (8G7G3/1). Twenty-seven adenocarcinomas (18%) were positive for p63 to a variable extent, with diffuse reaction being seen in 13 tumors (8.7%). p63 expression was seen in all subtypes of adenocarcinomas, except for the mucinous type. p40 was negative in all adenocarcinomas. All squamous cell carcinomas were diffusely positive for both p63 and p40. Four of 27 p63-positive adenocarcinomas were negative for TTF-1. p63 expression is not uncommonly seen in adenocarcinomas, whereas ΔNp63 (p40) expression is specific for squamous cell carcinoma, with sensitivity comparable to that of p63 expression. Presence of p63-positive cells in poorly differentiated lung adenocarcinoma may be erroneously interpreted as evidence of squamous cell differentiation. p40 appears to be a more reliable marker for squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22367298     DOI: 10.1097/PAS.0b013e3182498f2b

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  40 in total

1.  STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma.

Authors:  Yukihiro Otaka; Susumu Rokudai; Kyoichi Kaira; Michiru Fujieda; Ikuko Horikoshi; Reika Iwakawa-Kawabata; Shinji Yoshiyama; Takehiko Yokobori; Yoichi Ohtaki; Kimihiro Shimizu; Tetsunari Oyama; Jun'ichi Tamura; Carol Prives; Masahiko Nishiyama
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

2.  Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis.

Authors:  Kyuichi Kadota; Jun-ichi Nitadori; Natasha Rekhtman; David R Jones; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2015-09       Impact factor: 6.394

Review 3.  Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  E Felip; Á Concha; J de Castro; J Gómez-Román; P Garrido; J Ramírez; D Isla; J Sanz; L Paz-Ares; F López-Ríos
Journal:  Clin Transl Oncol       Date:  2014-10-29       Impact factor: 3.405

4.  Pulmonary adenocarcinoma histology.

Authors:  Erik Thunnissen
Journal:  Transl Lung Cancer Res       Date:  2012-12

5.  ΔNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens.

Authors:  Wei Zhao; Hui Wang; Yan Peng; Bo Tian; Lei Peng; Da-Chuan Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

6.  Immunostaining of ∆Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast.

Authors:  Verena Sailer; Christine Lüders; Walther Kuhn; Volker Pelzer; Glen Kristiansen
Journal:  Virchows Arch       Date:  2015-04-08       Impact factor: 4.064

7.  Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma.

Authors:  Marie-Christine Aubry; Anja Roden; Stephen J Murphy; George Vasmatzis; Sarah H Johnson; Faye R Harris; Geoffrey Halling; Ryan A Knudson; Rhett P Ketterling; Andrew L Feldman
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

8.  Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.

Authors:  Lester J Layfield; Sinchita Roy-Chowdhuri; Zubair Baloch; Hormoz Ehya; Kim Geisinger; Susan J Hsiao; Oscar Lin; Neal I Lindeman; Michael Roh; Fernando Schmitt; Nikoletta Sidiropoulos; Paul A VanderLaan
Journal:  Diagn Cytopathol       Date:  2016-08-26       Impact factor: 1.582

Review 9.  Prognostic and predictive biomarkers in lung cancer. A review.

Authors:  Erik Thunnissen; Kimberly van der Oord; Michael den Bakker
Journal:  Virchows Arch       Date:  2014-01-14       Impact factor: 4.064

10.  The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer.

Authors:  Ming-Hui Ao; Hui Zhang; Lynne Sakowski; Rajni Sharma; Peter B Illei; Edward Gabrielson; Frederic Askin; Qing Kay Li
Journal:  Hum Pathol       Date:  2014-01-25       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.